Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

189 related articles for article (PubMed ID: 24237755)

  • 1. Fluorodeoxyglucose positron emission tomography and chemotherapy-related tumor marker expression in non-small cell lung cancer.
    Duan XY; Wang W; Wang JS; Shang J; Gao JG; Guo YM
    BMC Cancer; 2013 Nov; 13():546. PubMed ID: 24237755
    [TBL] [Abstract][Full Text] [Related]  

  • 2. SUVmax of 18F-FDG PET/CT correlates to expression of major chemotherapy-related tumor markers and serum tumor markers in gastric adenocarcinoma patients.
    Bai L; Guo CH; Zhao Y; Gao JG; Li M; Shen C; Guo YM; Duan XY
    Oncol Rep; 2017 Jun; 37(6):3433-3440. PubMed ID: 28498457
    [TBL] [Abstract][Full Text] [Related]  

  • 3. 18F-fludrodeoxyglucose maximal standardized uptake value and metabolic tumor burden are associated with major chemotherapy-related tumor markers in NSCLC patients.
    Bai L; Guo C; Wang J; Liu X; Li Y; Li M; Guo Y; Duan X
    Onco Targets Ther; 2016; 9():6315-6324. PubMed ID: 27789962
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Fluorodeoxyglucose positron emission tomography and tumor marker expression in non-small cell lung cancer.
    Taylor MD; Smith PW; Brix WK; Wick MR; Theodosakis N; Swenson BR; Kozower BD; Lau CL; Jones DR
    J Thorac Cardiovasc Surg; 2009 Jan; 137(1):43-8. PubMed ID: 19154901
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Correlations between selected tumor markers and fluorodeoxyglucose maximal standardized uptake values in esophageal cancer.
    Taylor MD; Smith PW; Brix WK; Wick MR; Theodosakis N; Swenson BR; Kozower BD; Jones DR
    Eur J Cardiothorac Surg; 2009 Apr; 35(4):699-705. PubMed ID: 19136271
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Primary tumor SUVmax measured on (18)F-FDG PET-CT correlates with histologic grade and pathologic stage in non-small cell lung cancer].
    Zhao SJ; Wu N; Zheng R; Liu Y; Zhang WJ; Liang Y; Zhang H; Li XM
    Zhonghua Zhong Liu Za Zhi; 2013 Oct; 35(10):754-7. PubMed ID: 24378097
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prognostic value of FDG uptake in primary inoperable non-small cell lung cancer.
    Tong AN; Han SR; Yan P; Gong H; Zhao H; Yao H; Wang YM
    Med Oncol; 2014 Jan; 31(1):780. PubMed ID: 24326983
    [TBL] [Abstract][Full Text] [Related]  

  • 8. ERCC1 and the efficacy of cisplatin in patients with resected non-small cell lung cancer.
    Li C; Liu M; Yan A; Liu W; Hou J; Cai L; Dong X
    Tumour Biol; 2014 Dec; 35(12):12707-12. PubMed ID: 25217323
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Combination of Fluorine-18 Fluorodeoxyglucose Positron-Emission Tomography/Computed Tomography (¹⁸F-FDG PET/CT) and Tumor Markers to Diagnose Lymph Node Metastasis in Non-Small Cell Lung Cancer (NSCLC): A Retrospective and Prospective Study.
    Zhai X; Guo Y; Qian X
    Med Sci Monit; 2020 Jun; 26():e922675. PubMed ID: 32483109
    [TBL] [Abstract][Full Text] [Related]  

  • 10. FDG-PET parameters predicting mediastinal malignancy in lung cancer.
    Serra Fortuny M; Gallego M; Berna L; Montón C; Vigil L; Masdeu MJ; Fernández-Villar A; Botana MI; Cordovilla R; García-Luján R; Cases E; Monsó E
    BMC Pulm Med; 2016 Dec; 16(1):177. PubMed ID: 27931198
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Timing of fluorodeoxyglucose positron emission tomography maximum standardized uptake value for diagnosis of local recurrence of non-small cell lung cancer after stereotactic body radiation therapy.
    Tan D; Gill S; Loh N
    Cancer Med; 2020 Oct; 9(20):7469-7476. PubMed ID: 32846054
    [TBL] [Abstract][Full Text] [Related]  

  • 12. (18)F-fluorodeoxyglucose positron emission tomography versus computed tomography in predicting histopathological response to epidermal growth factor receptor-tyrosine kinase inhibitor treatment in resectable non-small cell lung cancer.
    van Gool MH; Aukema TS; Schaake EE; Rijna H; Codrington HE; Valdés Olmos RA; Teertstra HJ; van Pel R; Burgers SA; van Tinteren H; Klomp HM
    Ann Surg Oncol; 2014 Sep; 21(9):2831-7. PubMed ID: 24845729
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Correlation between EGFR gene mutation, cytologic tumor markers, 18F-FDG uptake in non-small cell lung cancer.
    Cho A; Hur J; Moon YW; Hong SR; Suh YJ; Kim YJ; Im DJ; Hong YJ; Lee HJ; Kim YJ; Shim HS; Lee JS; Kim JH; Choi BW
    BMC Cancer; 2016 Mar; 16():224. PubMed ID: 26979333
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The maximum standardized uptake value of fluorodeoxyglucose positron emission tomography of the primary tumour is a good predictor of pathological nodal involvement in clinical N0 non-small-cell lung cancer.
    Miyasaka Y; Suzuki K; Takamochi K; Matsunaga T; Oh S
    Eur J Cardiothorac Surg; 2013 Jul; 44(1):83-7. PubMed ID: 23233074
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Fluorine 18 fluorodeoxyglucose PET/CT volume-based indices in locally advanced non-small cell lung cancer: prediction of residual viable tumor after induction chemotherapy.
    Soussan M; Cyrta J; Pouliquen C; Chouahnia K; Orlhac F; Martinod E; Eder V; Morère JF; Buvat I
    Radiology; 2014 Sep; 272(3):875-84. PubMed ID: 24761836
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Role of [¹⁸F]FDG PET in prediction of KRAS and EGFR mutation status in patients with advanced non-small-cell lung cancer.
    Caicedo C; Garcia-Velloso MJ; Lozano MD; Labiano T; Vigil Diaz C; Lopez-Picazo JM; Gurpide A; Zulueta JJ; Richter Echevarria JA; Perez Gracia JL
    Eur J Nucl Med Mol Imaging; 2014 Nov; 41(11):2058-65. PubMed ID: 24990403
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Expression of excision repair cross-complementation group 1 protein predicts poor outcome in advanced non-small cell lung cancer patients treated with platinum-based doublet chemotherapy.
    Lee HW; Choi YW; Han JH; Kim JH; Jung JH; Jeong SH; Kang SY; Choi JH; Oh YT; Park KJ; Hwang SC; Sheen SS
    Lung Cancer; 2009 Sep; 65(3):377-82. PubMed ID: 19150580
    [TBL] [Abstract][Full Text] [Related]  

  • 18. New insight on the correlation of metabolic status on
    Wang Y; Zhao N; Wu Z; Pan N; Shen X; Liu T; Wei F; You J; Xu W; Ren X
    Eur J Nucl Med Mol Imaging; 2020 May; 47(5):1127-1136. PubMed ID: 31502013
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Volume-based assessment by (18)F-FDG PET/CT predicts survival in patients with stage III non-small-cell lung cancer.
    Hyun SH; Ahn HK; Kim H; Ahn MJ; Park K; Ahn YC; Kim J; Shim YM; Choi JY
    Eur J Nucl Med Mol Imaging; 2014 Jan; 41(1):50-8. PubMed ID: 23948859
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Value of
    Lv Z; Fan J; Xu J; Wu F; Huang Q; Guo M; Liao T; Liu S; Lan X; Liao S; Geng W; Jin Y
    Eur J Nucl Med Mol Imaging; 2018 May; 45(5):735-750. PubMed ID: 29164298
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.